Baricitinib: First Global Approval

2017/03/13 by Anthony Markham · 25 citations
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Rheumatoid Arthritis Research and Therapies #Cytokine Signaling Pathways and Interactions #Pharmacological Effects of Natural Compounds

paper · doi:10.1007/s40265-017-0723-3

Cited by

• IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. [europepmc]
• Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. [europepmc]
• Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. [europepmc]
• Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. [europepmc]
• COVID-19: The Immune Responses and Clinical Therapy Candidates. [europepmc]
• Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. [europepmc]
• Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. [europepmc]
• Baricitinib: From Rheumatoid Arthritis to COVID-19. [europepmc]
• Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway. [europepmc]
• Kinase Inhibitors as Underexplored Antiviral Agents. [europepmc]
• Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. [europepmc]
• Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. [europepmc]
• Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. [europepmc]
• Application of Baricitinib in Dermatology. [europepmc]
• Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease. [europepmc]
• A Comprehensive Overview of Globally Approved JAK Inhibitors. [europepmc]
• The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. [europepmc]
• Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus? [europepmc]
• Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer's Disease Progression. [europepmc]
• Visible Light Photoredox-Catalyzed Decarboxylative Alkylation of 3-Aryl-Oxetanes and Azetidines via Benzylic Tertiary Radicals and Implications of Benzylic Radical Stability. [europepmc]
• A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. [europepmc]
• Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword. [europepmc]
• SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis. [europepmc]
• Innovation of 6-sulfonamide-2 H -chromene derivatives as antidiabetic agents targeting α-amylase, α-glycosidase, and PPAR-γ inhibitors with in silico molecular docking simulation. [europepmc]
• Regulation of bone homeostasis: signaling pathways and therapeutic targets. [europepmc]